Cyto-Cellect® Human IgG Kappa and Viability Assay Kit launched for efficient single-cell selection

• First multiplexed solution introduced with state-of-the-art Cyto-Mine® Chroma platform for more efficient biotherapeutic development 

• Utilizes advanced picodroplet microfluidics technology to integrate analysis of antibody productivity and cell viability of monoclonal antibody producing cells

Cambridge, UK, [31st March 2025]:  Sphere Bio, a leading provider of innovative picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, today announced the launch of the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit, the first multiplexed assay developed specifically for the company’s new Cyto-Mine® Chroma.

The Cyto-Mine® Chroma platform uses fluorescence-based assays in picodroplets to select single cells based on secreted, surface, and/or intracellular markers. Aided by the new multiplexing capability of the Chroma system, the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit represents a significant advancement enabling customers to complete their work faster and at lower cost, while simultaneously improving the quality and viability of cells (clones) that are selected.  

By simultaneously detecting secreted antibodies and assessing a viability stain on the cell surface, this new assay enables high-throughput screening of viable, high-producing clones in a single automated workflow. Preliminary data indicate that approximately five percent of selected high-producing clones are apoptotic (dead or dying).  Screening out these clones at an early stage reduces the risk of false positives and ensures only the highest producers are selected for downstream analysis or development. 

Key features and benefits of Cyto-Cellect® Human IgG Kappa and Viability Assay Kit combined with the power of Cyto-Mine® Chroma include: 

The launch of this important addition to Sphere Bio’s product portfolio represents a significant milestone in the company’s mission to deliver transformative solutions for cell line development, setting new benchmarks for efficiency and reliability in the industry. 

“Our new assay kit is a game-changer for single-cell workflows. By integrating viability assessment with antibody detection, we can ensure that only the healthiest, most productive cells are selected, significantly improving the efficiency and outcomes of our customers’ research.” 

“The Cyto-Cellect® Human IgG Kappa and Viability Assay Kit leverages the advanced capabilities of Cyto-Mine® Chroma to deliver unparalleled precision in single-cell analysis. The new assay represents the first launch in our roadmap of multiplex assays compatible with Chroma, bringing advanced multiplexing capabilities to our customers through our expanding portfolio of cutting-edge tools and solutions to accelerate scientific discovery.”